How it works, simply
It mimics a hormone signal involved in fullness and food intake.
What the evidence tells us
Evidence for cagrilintide alone must be separated from evidence for CagriSema.
No study-by-study evidence summary has been verified for this profile yet. The explanation above describes its purpose and limits, not a proven benefit for every use.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This guide does not establish a safe dose, interaction profile or long-term safety for self-use. Effects reported for one route or formulation may not apply to another.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Activates amylin receptors and is being studied alone and with semaglutide.
Sponsor or developer: Novo Nordisk
Studied or labeled topics: Obesity, Type 2 diabetes
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
Product labels and further research
These directories help locate records. They are not individual studies supporting every statement.
Readability updated October 10, 2026. Evidence review: Primary-source review pending. A wording update is not a new clinical review.